Crofelemer Shows Promising Results in Reducing TPN for Rare Diseases

Jaguar Health, Inc. announced preliminary results from a study evaluating crofelemer, a plant-based drug, for patients with microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). The results indicate reductions in total parenteral nutrition (TPN) needs by up to 27% in MVID patients and 12.5% in SBS-IF patients. These findings were presented at the Annual ELITE PED-GI Congress.

Currently, no approved drugs exist for MVID, a severe pediatric disorder. The lack of treatments highlights the significance of crofelemer's potential. Jaguar Health aims to include it in the European Medicines Agency's PRIME program and the FDA's Breakthrough Therapies program for faster regulatory approvals.

The study's principal investigator, Dr. Mohamad Miqdady, emphasizes crofelemer's novel mechanism may improve patients' quality of life by lowering TPN reliance and associated risks. The company is also exploring further trials in the US, EU, and Middle East.